We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)'s share was ...

He added that the US market relies heavily on generic drugs rather than branded products, which Novo Nordisk does not sell. Competitor Eli Lilly (LLY) recently announced a $27 billion investment in ...

Novo Nordisk (NVO) remains a dominant force in diabetes and obesity treatments, yet the stock is currently trading below its fair value. Despite a recent decline following disappointing trial results ...